Tags

Type your tag names separated by a space and hit enter

Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
Ann Neurol. 2006 Feb; 59(2):282-8.AN

Abstract

OBJECTIVE

The objective of the present study was to investigate the effect of docosahexaenoic acid (DHA), a polyunsaturated fatty acid (omega-3), on levodopa-induced dyskinesias (LIDs) in parkinsonian 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys.

METHODS

We explored the effect of DHA in two paradigms. First, a group of MPTP monkeys was primed with levodopa for several months before introducing DHA. A second group of MPTP monkeys (de novo) was exposed to DHA before levodopa therapy.

RESULTS

DHA administration reduced LIDs in both paradigms without alteration of the anti-parkinsonian effect of levodopa indicating that DHA can reduce the severity or delay the development of LIDs in a nonhuman primate model of Parkinson's disease.

INTERPRETATION

These results suggest that DHA can reduce the severity or delay the development of LIDs in a nonhuman primate model of Parkinson's disease. DHA may represent a new approach to improve the quality of life of Parkinson's disease patients.

Authors+Show Affiliations

Centre de recherche en Neurosciences, Centre Hospitalier Universitaire de Québec (CHUQ), Ste-Foy, Quebec, Canada.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16437566

Citation

Samadi, Pershia, et al. "Docosahexaenoic Acid Reduces Levodopa-induced Dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Monkeys." Annals of Neurology, vol. 59, no. 2, 2006, pp. 282-8.
Samadi P, Grégoire L, Rouillard C, et al. Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Ann Neurol. 2006;59(2):282-8.
Samadi, P., Grégoire, L., Rouillard, C., Bédard, P. J., Di Paolo, T., & Lévesque, D. (2006). Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Annals of Neurology, 59(2), 282-8.
Samadi P, et al. Docosahexaenoic Acid Reduces Levodopa-induced Dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Monkeys. Ann Neurol. 2006;59(2):282-8. PubMed PMID: 16437566.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. AU - Samadi,Pershia, AU - Grégoire,Laurent, AU - Rouillard,Claude, AU - Bédard,Paul J, AU - Di Paolo,Thérèse, AU - Lévesque,Daniel, PY - 2006/1/27/pubmed PY - 2006/4/28/medline PY - 2006/1/27/entrez SP - 282 EP - 8 JF - Annals of neurology JO - Ann Neurol VL - 59 IS - 2 N2 - OBJECTIVE: The objective of the present study was to investigate the effect of docosahexaenoic acid (DHA), a polyunsaturated fatty acid (omega-3), on levodopa-induced dyskinesias (LIDs) in parkinsonian 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys. METHODS: We explored the effect of DHA in two paradigms. First, a group of MPTP monkeys was primed with levodopa for several months before introducing DHA. A second group of MPTP monkeys (de novo) was exposed to DHA before levodopa therapy. RESULTS: DHA administration reduced LIDs in both paradigms without alteration of the anti-parkinsonian effect of levodopa indicating that DHA can reduce the severity or delay the development of LIDs in a nonhuman primate model of Parkinson's disease. INTERPRETATION: These results suggest that DHA can reduce the severity or delay the development of LIDs in a nonhuman primate model of Parkinson's disease. DHA may represent a new approach to improve the quality of life of Parkinson's disease patients. SN - 0364-5134 UR - https://www.unboundmedicine.com/medline/citation/16437566/Docosahexaenoic_acid_reduces_levodopa_induced_dyskinesias_in_1_methyl_4_phenyl_1236_tetrahydropyridine_monkeys_ L2 - https://doi.org/10.1002/ana.20738 DB - PRIME DP - Unbound Medicine ER -